Clinical Trial Update: GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating GnRH agonist for ovarian protection during cyclophosphamide therapy in rheumatic diseases was terminated; results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Interstitial Lung Disease
• Isolated Angiitis of the Cns
• Systemic Lupus Erythematosus
• Systemic Sclerosis with Interstitial Lung Disease
• Systemic Vasculitis

Drugs mentioned

• Lupron (leuprolide)
• Zoladex (goserelin)

Snippet

Sponsor: Joseph Mccune | Conditions: Lupus Erythematosus, Systemic, Systemic Vasculitis | Phase 3 | Status: TERMINATED | Results posted: 2017-06-27